Acticor Biotech (XPAR:ALACT) Cash-to-Debt : 1.13 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Acticor Biotech Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Acticor Biotech's cash to debt ratio for the quarter that ended in Jun. 2023 was 1.13.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Acticor Biotech could pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

The historical rank and industry rank for Acticor Biotech's Cash-to-Debt or its related term are showing as below:

XPAR:ALACT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.84 Med: 2.44 Max: 11.34
Current: 1.13

During the past 6 years, Acticor Biotech's highest Cash to Debt Ratio was 11.34. The lowest was 0.84. And the median was 2.44.

XPAR:ALACT's Cash-to-Debt is ranked worse than
74.81% of 1540 companies
in the Biotechnology industry
Industry Median: 6.52 vs XPAR:ALACT: 1.13

Acticor Biotech Cash-to-Debt Historical Data

The historical data trend for Acticor Biotech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Acticor Biotech Cash-to-Debt Chart

Acticor Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

8.50

11.34

2.96

4.19

0.84

Acticor Biotech Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Cash-to-Debt	Get a 7-Day Free Trial				1.92	4.19	1.90	0.84	1.13

Competitive Comparison of Acticor Biotech's Cash-to-Debt

For the Biotechnology subindustry, Acticor Biotech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acticor Biotech's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acticor Biotech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Acticor Biotech's Cash-to-Debt falls into.

Acticor Biotech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Acticor Biotech's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	6.599	/	(0.801	+	7.062)
	=	0.84

Acticor Biotech's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	7.955	/	(2.705	+	4.342)
	=	1.13

Acticor Biotech (XPAR:ALACT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Acticor Biotech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Acticor Biotech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Acticor Biotech (XPAR:ALACT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acticor Biotech SA (XPAR:ALACT) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

7V7:Germany

Address

82 Avenue du Maine, Wojo Building, Paris, FRA, 75014

Website

https://www.acticor-biotech.com

Acticor Biotech SA is a clinical stage biopharmaceutical company. It is developing a treatment for cardiovascular emergencies, with a primary focus on Acute Ischemic Stroke.

Acticor Biotech (XPAR:ALACT) Headlines

No Headlines